Association of pretreatment SUVmax of cervix and SCC‐antigen with FIGO2018 stage in Stage IIB–IVB squamous cervical cancer and relationship to prognosis
Abstract
Objective
To evaluate the association of pretreatment maximum standardized 18F‐fluorodeoxyglucose uptake value (SUVmax) of cervix and serum squamous cell carcinoma antigen (SCC‐ag) with FIGO2018 stage and prognosis among women with Stage IIB–IVB squamous cervical cancer.
Methods
Retrospective study of 116 women with FIGO2018 Stage IIB–IVB cervical cancer treated in Hangzhou, China, 2013–2015. The relationship between pretreatment SUVmax or SCC‐ag and prognostic factors was evaluated by univariate and multivariate analyses.
Results
Women were stratified by mean SUVmax and mean SCC‐ag. There was a significant difference between low (<12.9) and high (≥12.9) SUVmax groups in menopause (P = 0.004), FIGO2018 stage (P = 0.015), and survival rate (P < 0.001). The low group had better overall and progress‐free survival by Kaplan–Meier evaluation (both P = 0.022). High SCC‐ag (≥14.6 ng/mL) was associated with FIGO2018 stage (P = 0.038) and distant metastasis (P = 0.011). There was a significant correlation between SUVmax and serum SCC‐ag (P = 0.026). In multivariate Cox regression analyses, FIGO2018 stage (P = 0.019) and SUVmax of cervix (P = 0.015) were independent predictors of poor outcome in squamous cervical cancer.
Conclusion
Both SUVmax of cervix and SCC‐ag were associated with FIGO2018 stage in squamous cervical cancer. Pretreatment high SUVmax of cervix and advanced FIGO2018 stage might indicate a poor prognosis.